H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.
Madrigal Pharmaceuticals Inc. (MDGL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,141,701 | $1,247,198,160 | 7.3% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 1,807,500 | $1,052,579,550 | -2% | 10.35% |
| 3. | Paulson & Co John Paulson | 1,707,522 | $994,358,361 | -11% | 30.48% |
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 270,151 | $157,319,733 | +2% | 0.61% |
| 5. | Armistice Capital Steven Boyd | 265,705 | $154,730,650 | +122% | 1.84% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $392.24 | 9,362 | $3,672,178.03 | 1,947,968 | 2025-08-20 | Filing | |
| $392.24 | 862 | $338,113.38 | 202,813 | 2025-08-20 | Filing | |
| $389.89 | 2,506 | $977,058.83 | 1,938,606 | 2025-08-20 | Filing | |
| $389.89 | 231 | $90,064.08 | 201,951 | 2025-08-20 | Filing | |
| $389.00 | 366 | $142,374.00 | 1,936,100 | 2025-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $494.59 | 570 | $281,916.30 | 9,122 | 2026-01-26 | Filing | |
| $492.42 | 340 | $167,422.80 | 9,692 | 2026-01-26 | Filing | |
| $492.42 | 1,577 | $776,546.34 | 148,497 | 2026-01-26 | Filing | |
| $492.42 | 647 | $318,595.74 | 452,704 | 2026-01-26 | Filing | |
| $501.40 | 429 | $215,100.60 | 8,481 | 2026-01-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,993,687 | $1,161,003,688 | 11.63% | |
| 2. | 1,808,894 | $1,053,391,331 | 0.02% | |
| 3. | 1,644,750 | $957,803,431 | 0.02% | |
| 4. | 1,584,843 | $918,203,904 | 0.41% | |
| 5. | 583,003 | $339,505,967 | 0.01% |
News See All
11 High Short Interest Stocks to Buy Right Now
On December 8, Bob Doll, Crossmark Global Investments CEO and CIO, joined CNBC’s ‘Squawk on the Street’ to discuss the latest market trends and his expectations for the Fed.
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2025 Earnings Call Transcript November 4, 2025Madrigal Pharmaceuticals, Inc. misses on earnings expectations.
TD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra Approval
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the most shorted stocks right now.
10 Most Shorted Stocks Right Now
Short interest has become one of the most closely followed indicators in today’s market.
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the current market scenario...
Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Call Transcript August 5, 2025Madrigal Pharmaceuticals, Inc. beats earnings expectations.
Hedge Fund Resource Center Billionaire Hedge Funds
